MA71605A - Compositions de nanoparticules pour le traitement de la douleur neuropathique - Google Patents

Compositions de nanoparticules pour le traitement de la douleur neuropathique

Info

Publication number
MA71605A
MA71605A MA71605A MA71605A MA71605A MA 71605 A MA71605 A MA 71605A MA 71605 A MA71605 A MA 71605A MA 71605 A MA71605 A MA 71605A MA 71605 A MA71605 A MA 71605A
Authority
MA
Morocco
Prior art keywords
treatment
neuropathic pain
nanoparticle compositions
nanoparticle
compositions
Prior art date
Application number
MA71605A
Other languages
English (en)
Inventor
Marie-Edith MEYRE
Céline BERJAUD
Frédéric SEDEL
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MA71605A publication Critical patent/MA71605A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/242Gold; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5115Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA71605A 2022-07-28 2023-07-28 Compositions de nanoparticules pour le traitement de la douleur neuropathique MA71605A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22306126 2022-07-28
EP23749036.2A EP4561545A1 (fr) 2022-07-28 2023-07-28 Compositions de nanoparticules pour le traitement de la douleur neuropathique
PCT/EP2023/070958 WO2024023282A1 (fr) 2022-07-28 2023-07-28 Compositions de nanoparticules pour le traitement de la douleur neuropathique

Publications (1)

Publication Number Publication Date
MA71605A true MA71605A (fr) 2025-05-30

Family

ID=83318934

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71605A MA71605A (fr) 2022-07-28 2023-07-28 Compositions de nanoparticules pour le traitement de la douleur neuropathique
MA71604A MA71604A (fr) 2022-07-28 2023-07-28 Compositions de nanoparticules pour le traitement de la douleur neuropathique

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA71604A MA71604A (fr) 2022-07-28 2023-07-28 Compositions de nanoparticules pour le traitement de la douleur neuropathique

Country Status (13)

Country Link
US (1) US20260102427A1 (fr)
EP (2) EP4561545A1 (fr)
JP (2) JP2025525072A (fr)
KR (2) KR20250040652A (fr)
CN (2) CN119768156A (fr)
AR (2) AR130054A1 (fr)
AU (2) AU2023313035A1 (fr)
CA (2) CA3261285A1 (fr)
IL (2) IL318358A (fr)
MA (2) MA71605A (fr)
MX (2) MX2025001088A (fr)
TW (2) TW202417022A (fr)
WO (2) WO2024023281A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118543024B (zh) * 2024-07-26 2024-10-11 首都医科大学附属北京同仁医院 一种导电微针贴片及其制备方法及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102138978B1 (ko) 2018-11-06 2020-07-28 서울대학교산학협력단 나노입자 구조체 및 그 형성 방법

Also Published As

Publication number Publication date
MA71604A (fr) 2025-05-30
US20260102427A1 (en) 2026-04-16
JP2025525072A (ja) 2025-08-01
WO2024023282A1 (fr) 2024-02-01
TW202417022A (zh) 2024-05-01
IL318358A (en) 2025-03-01
JP2025525047A (ja) 2025-08-01
CA3261285A1 (fr) 2024-02-01
EP4561544A1 (fr) 2025-06-04
EP4561545A1 (fr) 2025-06-04
MX2025001088A (es) 2025-03-07
AR130054A1 (es) 2024-10-30
WO2024023281A1 (fr) 2024-02-01
KR20250040652A (ko) 2025-03-24
AR130053A1 (es) 2024-10-30
MX2025001087A (es) 2025-03-07
AU2023313329A1 (en) 2025-01-30
CA3261299A1 (fr) 2024-02-01
CN119768156A (zh) 2025-04-04
TW202419095A (zh) 2024-05-16
KR20250036155A (ko) 2025-03-13
IL318359A (en) 2025-03-01
CN119816302A (zh) 2025-04-11
AU2023313035A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
EP3737361A4 (fr) Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie
EP3765611A4 (fr) Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3426258A4 (fr) Compositions d'antibiotiques stéroïdiens cationiques pour le traitement de tissu dermique
EP3600281A4 (fr) Traitement d'association pour le traitement ou la prévention de tumeurs
EP3890747A4 (fr) Compositions pour le traitement de la fibrose et de l'inflammation
EP3986863A4 (fr) Inhibiteurs de glycolate oxydase pour le traitement d'une maladie
EP3691639A4 (fr) Composés monobactames de chromane pour le traitement d'infections bactériennes
EP3664795A4 (fr) Cannabis et ses dérivés pour le traitement de la douleur et de l'inflammation associées à la pulpe dentaire et de la régénération osseuse associée à des défauts osseux de la mâchoire
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
MA51738A (fr) Composés pour le traitement de la douleur
MA55084A (fr) Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
EP3648769A4 (fr) N-acyl amides dérivés du microbiote humain pour le traitement d'une maladie humaine
MA71604A (fr) Compositions de nanoparticules pour le traitement de la douleur neuropathique
EP3758716A4 (fr) Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium
MA71734A (fr) Composés pour le traitement du cancer
MA55982A (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4209216A4 (fr) Composition pharmaceutique pour le traitement de tumeurs
EP4251143A4 (fr) Composition de benzènesulfonamide pour le traitement du mélanome
EP3827831A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la stéatohépatite non alcoolique
EP3996729C0 (fr) Composition pour la prévention ou le traitement de la dépression ou de l'anxiété
MA55752A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies
EP3826633A4 (fr) Compositions pour le traitement de l'hypertension
EP3838272A4 (fr) Composition pour la prévention ou le traitement d'une maladie neurodégénérative
EP3886809A4 (fr) Méthodes et compositions pour le traitement de l'arthrose